君实生物：特瑞普利单抗注射液第13项适应症上市申请获批

财中社05-21 18:36

　　5月21日，君实生物（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞普利单抗（商品名：拓益®）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。

　　公告中提到，特瑞普利单抗注射液于2021年已获批用于晚期尿路上皮癌的二线及以上治疗，是我国首个获批的晚期尿路上皮癌非选择性人群适应症的免疫治疗药物。

　　2026年一季度，君实生物实现收入7.26亿元，归母净利润-2056万元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2637387686?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-21 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637387686","market":"us","top_or_hot":-1,"title":"君实生物：特瑞普利单抗注射液第13项适应症上市申请获批","media":"财中社","content":"<html><body><div>\n<p>　　5月21日，<span><a href=\"https://laohu8.com/S/01877\">君实生物</a></span>（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞<a href=\"https://laohu8.com/S/300630\">普利</a>单抗（商品名：拓益®）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。</p><p>　　公告中提到，特瑞普利单抗注射液于2021年已获批用于晚期尿路上皮癌的二线及以上治疗，是我国首个获批的晚期尿路上皮癌非选择性人群适应症的<span>免疫治疗</span><span></span>药物。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01877\" target=\"_blank\" web=\"1\">君实生物</span>实现收入7.26亿元，归母净利润-2056万元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物：特瑞普利单抗注射液第13项适应症上市申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物：特瑞普利单抗注射液第13项适应症上市申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　5月21日，<span><a href=\"https://laohu8.com/S/01877\">君实生物</a></span>（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞<a href=\"https://laohu8.com/S/300630\">普利</a>单抗（商品名：拓益®）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。</p><p>　　公告中提到，特瑞普利单抗注射液于2021年已获批用于晚期尿路上皮癌的二线及以上治疗，是我国首个获批的晚期尿路上皮癌非选择性人群适应症的<span>免疫治疗</span><span></span>药物。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01877\" target=\"_blank\" web=\"1\">君实生物</span>实现收入7.26亿元，归母净利润-2056万元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202605213745358513.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605213745358513.html","article_id":"2637387686","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637387686","pubTimestamp":1779359760,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"5月21日，君实生物（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞普利单抗（商品名：拓益?）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1583":"高瓴概念","01877":"君实生物","IPOS":"Renaissance International IPO ETF","BK1161":"生物科技"},"translate_title":"Junshi Bio: The marketing application for the 13th indication of toripalimab injection was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"01877":1.5},"content_text":"5月21日，君实生物（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞普利单抗（商品名：拓益®）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。　　公告中提到，特瑞普利单抗注射液于2021年已获批用于晚期尿路上皮癌的二线及以上治疗，是我国首个获批的晚期尿路上皮癌非选择性人群适应症的免疫治疗药物。　　2026年一季度，君实生物实现收入7.26亿元，归母净利润-2056万元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637387686","isCrawlerRequest":true}